National Cancer Institute CRO Aviano posted this:Mechanisms of p53 inactivation in TP53 wild type tumors and factors affecting sensitivity to MDM2 inhibitorsThe research group led by Dr Roberta Maestro demonstrated that the overexpression of the protein Twist, detectable in a large fraction of sarcomas but also in a fraction of carcinomas, facilitates the MDM2-mediated degradation of p53 by making p53 more susceptible to MDM2 attack. The p53:MDM2 interplay is the target of a number of compounds currently under clinical trials. These compounds (MDM2i) are aimed at alleviating p53 from MDM2-mediated degradation and hence at restoring the p53 tumor suppressive activity. Maestro and coworkers gathered data indicating that the expression of Twist may significantly impact on the activity of these drugs.
Yissum - Research Development Company of the Hebrew University posted this:Novel Naturally Occurring Compounds for Treating Cystic FibrosisCannabis project Derivatives of cannabinoids have an antimicrobial and anti biofilm effect on pseudomonas and candida which are major ethological pathogenic factors in CF Project ID : 6-2019-6720
Ukrainian Laboratories posted this:Computer aided drug discovery servicesOtava Research Institute helps researchers around the world develop advanced solutions for the variety of research projects maximizing their efficiencies, and, most of all, respecting their budgets. Our experts are involved in the development of leading compounds at any stage of the R&D process: starting from target identification to lead optimization
Consejo Superior de Investigaciones Científicas posted this:Transphagocytic T cells as anti cancer immunotherapyTransphagocytic T cells as anti cancer immunotherapy CSIC´s research group, in collaboration with scientists from the Centre of Molecular Biology “Severo Ochoa” (CBMSO-CSIC), the Autónoma University of Madrid and the Health Research Institute of the “La Princesa” University Hospital, developed a new method for anti-cancer immunotherapy based on transphagocytic lymphocytes (tiCD4+ T cells) Companies interested in a patent license or investors for creation of a start-up are being sought. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Purine derivatives for the treatment of neurodegenerative diseasesCSIC has synthesized several substituted purine derivatives that are capable of inhibiting the activity of the CDC7 kinase. This inhibitory activity makes them useful for the treatment of neurological diseases. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Kits for cell culture based on hydrogel coatingsCSIC and Complutense University of Madrid have developed new kits for cell culture based on cytocompatible hydrogels coated onto stiff substrates. Due to the excellent adhesion of the hydrogel to these substrates is possible to have mechanically robust platforms, easy to handle as required in a cellular biology laboratory. These new kits have been successfully tested showing an excellent cellular proliferation on the surface of the hydrogel. Besides, this technology allows the detachment of a cell monolayer without the need of chemical or biological agents preserving the viability of cell harvesting. Industrial partners from the biotechnology with expertise in cell culture are being sought to collaborate through a patent license agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Regulatory compounds of synaptic transmission for the treatment of neurological diseasesThe CSIC and IRYCIS (Ramón y Cajal Institute for Health Research) have developed a group of compounds. These compounds have the ability to regulate the number of synapses that are formed between neurons, as well as the probability that neurotransmitters are released from these, because they have the capability of modulate the interactions that take place between the regulatory proteins NCS-1 and Ric8a that regulate these two independent processes. Due to these neuromodulatory properties, these compounds are useful for the treatment of neurological diseases as Alzheimer's disease, Huntington or Parkinson's diseases among others. Industrial partners from the ophthalmic or pharmaceutical industry are being sought to collaborate through a patent license agreement. An offer for Patent Licensing
Centre Technology Transfer CITTRU posted this:Hospital emissions: N2O abatementThe subject of the offer is catalyst, α-Al2O3 supported, dedicated to reduce the emission of N2O in a low temperature range. Application: Hospital gases collectors, nitric acid production plant emitters, adipic acic production plant emitters.
UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera
Laser Consult Ltd. posted this:Thyroid Hormone Action Indicator Transgenic Mouse: the in vivo model to promote thyroid hormone-related R&DA Hungarian academic research institute developed a Thyroid Hormone Action Indicator (THAI) Mouse, a transgenic mouse model to measure the authentic thyroid hormone signalling in a live animal. They are looking for potential partners that would be interested in licensing the THAI mouse model. The target users are companies developing thyromimetics.
Laijo Jose posted this:
Manager-Tech Transfer at Centre For Future (CFF)
Universidad de Alcalá-OTRI posted this:Compounds for the treatment of Leishmania infectionsThe research group Heterobetainas of the University of Alcalá presents the preparation and uses of a series of compounds that act as bioactive agents against the Leishmania parasite and as therapeutic agents in the treatment of this disease, in both, its visceral (LV) version and in the mucocutaneous one (CML). The group is looking for pharmaceutical companies interested in manufacturing an active ingredient for the formulation of a leishmanicidal drug based on these compounds. The group proposes the signing of a patent license agreement, a collaboration agreement or a commercial agreement with technical
Universidad de Alcalá-OTRI posted this:Endothelial microvesicles with microbicidal effect for the preparation of a medicament or for a direct useThe research group "Cell damage associated with senescence" of the University of Alcalá presents the microbicidal capacity of endothelial microvesicles. These vesicles destroy the main pathogens involved in sepsis and even strains derived from them resistant to multiple antibiotics. They have also been shown to be effective against the biofilms that form these microorganisms. The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies interested in the design of new medicines.
Yissum - Research Development Company of the Hebrew University posted this:Tissue DynamicsA company that provides services for toxicity level in molecules- for Pharma companies, maybe will produce a kit Project ID : 6-2017-4402